| A385 |
Vixarelimab Biosimilar(Anti-OSMR Reference Antibody)
Featured
|
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash. |
|
| A386 |
ASK8007 Biosimilar(Anti-Osteopontin Reference Antibody)
Featured
|
|
|
| A387 |
Janssen patent anti-CD200R1 Biosimilar（Anti-OX2R / CD200R1 Reference Antibody）
Featured
|
|
|
| A388 |
Orticumab Biosimilar（Anti-oxLDL Reference Antibody）
Featured
|
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement. |
|
| A389 |
Okayama U. patent anti-oxLDL Biosimilar(Anti-oxLDL Reference Antibody)
Featured
|
|
|
| A390 |
Zelminemab Biosimilar(Anti-PAC1 Reference Antibody)
Featured
|
Zelminemab (AMG-301) is a humanized monoclonal antibody that inhibits PACAP type I (PAC1) receptor. |
|
| A391 |
Lilly patent anti-PACAP Biosimilar(Anti-PACAP38 Reference Antibody)
Featured
|
|
|
| A392 |
Amgen patent anti-PAR-2 Biosimilar(Anti-PAR2 Reference Antibody)
Featured
|
|
|
| A393 |
PAR650097 Biosimilar(Anti-PAR2 Reference Antibody)
Featured
|
|
|
| A394 |
Regeneron patent anti-PAR-2 Biosimilar(Anti-PAR2 Reference Antibody)
Featured
|
|
|
| A395 |
U.Penn. patent anti-PCLA Biosimilar(Anti-PCLA Reference Antibody)
Featured
|
|
|
| A396 |
Recaticimab Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Recaticimab can bind to PCSK9 and mediate its degradation, increasing the level of low-density lipoprotein (LDL) receptors on the surface of liver cells, reducing the level of LDL in plasma, thereby lowering blood lipids. Recaticimab can be used for the study of hypercholesterolemia. |
|
| A397 |
Ralpancizumab Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke. |
|
| A398 |
RG-7652 Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
|
|
| A399 |
Lodelcizumab Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
Lodelcizumab is a monoclonal antibody. Lodelcizumab can be used for the research of hypercholesterolemia. |
|
| DC67023 |
Amvuttra
Featured
|
|
|
| DC67024 |
Inotersen
Featured
|
Inotersen is an antisense oligonucleotide that inhibits hepatic production of transthyretin (TTR).
The free form of the compound is prone to instability, it is advisable to consider the stable salt form (Inotersen sodium) that retains the same biological activity. |
|
| DC67025 |
Mipomersen
Featured
|
Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH).
The free form of the compound is prone to instability, it is advisable to consider the stable salt form (Mipomersen sodium) that retains the same biological activity. |
|
| DC67027 |
Onpattro
Featured
|
|
|
| DC67028 |
Pegaptanib
Featured
|
|
|
| DC67029 |
KT-413
Featured
|
KT-413 (example I-3) is a potent IRAK degrader. |
|
| A400 |
Ongericimab Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia. |
|
| A401 |
Tafolecimab Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia. |
|
| A402 |
Frovocimab Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9. |
|
| A403 |
Bococizumab Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia. |
|
| A404 |
Ebronucimab Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
Ebronucimab (AK102) is an IgG1-λ2 antibody targeting PCSK9 and is primarily expressed by CHO DG44 (Chinese Hamster Ovary) cells. |
|
| A405 |
Boehringer anti-PCSK9 Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
|
|
| A406 |
Merck patent anti-PCSK9 Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
|
|
| A407 |
Schering patent anti-PCSK9 Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
|
|
| A408 |
Dostarlimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively. |
|
